Medical Marijuana Competitive Intelligence Analysis report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the Medical Marijuana Market industry. A detailed picture of the competitive landscape is provided with summation of data from multiple sources with complete analysis of companies, patents, pipeline products, competitive benchmarking and therapeutic assessment of clinical products.
The fast development of the cannabis and its expanding appropriation over the therapeutic application has grabbed the eye of a large group of industry verticals running from pharmaceuticals to land and preparing ventures to advisory and consultancy administrations. While cannabis cultivators and producers are the most critical piece of the cannabis ecosystem, revenue comes significantly from Pharmaceutical organizations.
The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called cannabinoids, has led to some FDA-approved medications that contain cannabinoid chemicals in pill form. Continued research may lead to the approval of more medications.
The medical marijuana market report covers 12+ companies working in this domain, such as GW Pharmaceuticals, Canopy Growth Corporation, Aurora Cannabis, Auxly Cannabis Group and others. GW Pharmaceuticals has two medical marijuana products in the market; Epidiolex and Sativex. Epidiolex (cannabidiol) oral solution is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
The company profiles include but are not limited to business overview, products, and latest development activities focusing on collaborations and licensing deals, partnerships and agreements, acquisitions, product launches, awards and grants, and other latest developments.
Pipeline analysis of therapeutic drugs include but are not limited to brief drug description and product profile focusing on molecule type, phase of clinical development, drug developer, indication, and route of administration. Most pipeline products have oral route of administration and maximum clinical trials are focused on treatment of neuropathic pain.
The medical marijuana market report comprises of comparative pipeline therapeutics assessment by development phase, indication, and route of administration. There are various products in late stages of development which point towards a hopeful future in terms of products approvals. Neuropathic pain has been the most sought after indication for clinical trials, followed by spasticity in patients with multiple sclerosis, cancer pain, and others.